Home About us Contact
|
Home About us Contact | ||
|
|
||
Lymphoma Survivors (lymphoma + survivor)
Selected AbstractsFertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapyHEMATOLOGICAL ONCOLOGY, Issue 1 2007David C. Hodgson Abstract Although ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) chemotherapy is infrequently associated with premature amenorrhea, little is known about the success rate of women attempting pregnancy following ABVD. In the present study females treated for HL with ABVD chemotherapy without pelvic radiation therapy (RT) and who were alive without relapse ,3 years after treatment were identified from a clinical database and screened for inclusion. Using a standardized questionnaire, we determined the pregnancy rate (i.e. time-to-pregnancy, TTP) among survivors who had become pregnant, tried to become pregnant, or who had been sexually active for over 2 months without using contraception at any time following ABVD. The cumulative incidence of pregnancy was calculated using the Kaplan,Meier method. Cox proportional hazards models were constructed to compare the pregnancy rate among HL survivors to that reported by friend or sibling controls. Thirty-six female HL survivors, who had attempted pregnancy after ABVD treatment, and 29 controls, completed the survey. Eighteen patients (50%) received 2,4 cycles of ABVD, 16 (44%) received 4,6 cycles, and 2 (6%) received >6 cycles. The median TTP among both HL survivors and controls was 2.0 months. The 12-month pregnancy rates were 70% and 75%, respectively. The fertility ratio (FR) for HL survivors versus controls was 0.94 (95%CI,=,0.53,1.66; p,=,0.84) after adjusting for age and frequency of intercourse (where FR <,1 indicates subfertility). Age at treatment and the number of cycles of chemotherapy were not associated with pregnancy rate among HL survivors. Female HL patients who had survived without recurrence ,3 years and who had attempted pregnancy after ABVD did not experience significant sub-fertility. Copyright © 2006 John Wiley & Sons, Ltd. [source] Informational needs assessment of non-Hodgkin lymphoma survivors and their physicians,AMERICAN JOURNAL OF HEMATOLOGY, Issue 7 2010Daphne R. Friedman First page of article [source] Complementary and alternative medicine use among long-term lymphoma survivors: A pilot study,AMERICAN JOURNAL OF HEMATOLOGY, Issue 12 2009Thomas M. Habermann No published survey has specifically addressed the beliefs, knowledge, and usage of complementary and alternative medicine (CAM) in long-term (5,20 years) lymphoma survivors alone. In this pilot project, 95 subjects were randomly selected from a population of 2,475 long-term lymphoma survivors and mailed a questionnaire. The median time from lymphoma diagnosis to completion of the questionnaire was 11 years (range 6,20). Overall, 68% (95% CI: 54,80%) of the long-term lymphoma survivors reported that they have used CAM, a rate higher than the estimated usage rate reported for the general population The most commonly used modalities were chiropractic (39%, 95% CI: 27,53%) and massage therapy (21%, 95% CI: 12,34%). Less than 10% used meditation (5%, 95% CI: 1,15%) and relaxation (7%, 95% CI: 2,17%). In terms of common herbal usage, 5% (95% CI: 1,15%) had used St. John's Wort and 7% (95% CI: 2,17%) had used shark cartilage. Although none of the patients reported that CAM usage was directed specifically towards treating their lymphoma, 4% (95% CI: 0,12%) of patients reported that CAM could cure cancer, and 14% (95% CI: 6,26%) reported that CAM could increase their feeling of control over their health. This pilot study suggests that long-term lymphoma survivors appear to use CAM at a rate higher than the general population. The use of potential agents of risk by the survivors and the lack of access to potentially beneficial modalities highlights the need for further study of CAM in this population. Am. J. Hematol., 2009. © 2009 Wiley-Liss, Inc. [source] | ||||||||||